pSivida Corp PT Lowered to $2.75 (PSDV)
Ladenburg Thalmann cut their target price on shares of pSivida Corp (NASDAQ:PSDV) from $5.00 to $2.75 in a research note issued on Friday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Ladenburg Thalmann’s target price indicates a potential downside of 27.63% from the company’s current price.
A number of other analysts have also recently weighed in on PSDV. Analysts at Northland Capital Partners initiated coverage on shares of pSivida Corp in a research note to investors on Tuesday, October 8th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Northland Securities initiated coverage on shares of pSivida Corp in a research note to investors on Monday, October 7th. They set an “outperform” rating on the stock.
pSivida Corp (NASDAQ:PSDV) traded down 20.92% on Friday, hitting $3.005. 3,486,617 shares of the company’s stock traded hands. pSivida Corp has a 52-week low of $1.17 and a 52-week high of $5.60. The stock’s 50-day moving average is $4.21 and its 200-day moving average is $3.43. The company’s market cap is $80.5 million.
pSivida Corp (NASDAQ:PSDV) last issued its quarterly earnings data on Wednesday, September 25th. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.05. The company had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.65 million. On average, analysts predict that pSivida Corp will post $-0.58 earnings per share for the current fiscal year.
pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.